Full name
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study
NCT Number
NCT04954859
Geography
US
Non-US
Locations
Argentina, Bulgaria, Canada, China, France, Hong Kong, Italy, Japan, Poland, Romania, Russia, Singapore, South Africa, South Korea, Spain, Thailand, United Kingdom, United States
Primary Endpoints
- Percentage of Not-on-NA participants without loss of parent study primary outcome (PSPO). From primary endpoint assessment in the parent study up to Month 57
- Percentage of On-NA participants rolling over from studies 209668 and 209348 without loss of functional cure (FC) after NA-cessation in study 206882. From Month 3 up to Month 57
- Percentage of On-NA participants rolling over from study 217023 without loss of FC after NA-cessation in study 206882. From Month 3 up to Month 33
- Percentage of NA-cessated participants rolling over from studies 202009 and 219288 without loss of FC after NA-cessation in the parent study. From primary endpoint assessment in the parent study up to Month 33
Order
3
Disease
Version
Phase
2
Status
Recruiting